Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000804489 | SCV000944400 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2023-06-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002495093 | SCV002786671 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV003482313 | SCV004229524 | uncertain significance | not provided | 2023-02-16 | criteria provided, single submitter | clinical testing | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity (http://gnomad.broadinstitute.org). Computational tools disagree on the variant's effect on normal protein function. |
Breakthrough Genomics, |
RCV003482313 | SCV005194072 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Ambry Genetics | RCV004962819 | SCV005552806 | uncertain significance | Inborn genetic diseases | 2024-06-25 | criteria provided, single submitter | clinical testing | The c.2192C>T (p.T731M) alteration is located in exon 10 (coding exon 9) of the CACNA1H gene. This alteration results from a C to T substitution at nucleotide position 2192, causing the threonine (T) at amino acid position 731 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |